Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 957 of 6351
-
New immunotherapy cocktail targets Hard-to-Treat bowel cancer
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus other treatments in participants with MSI-H or dMMR Metastatic Stage IV Colorectal Cancer.
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New hope for kidney patients: drug may stop protein leak without lifelong pills
Disease control OngoingThis study will evaluate the efficacy, safety, pharmacodynamics, and pharmacokinetics (PK) of obinutuzumab compared with tacrolimus in participants with primary membranous nephropathy (pMN).
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Smart scans and blood tests could guide lymphoma treatment
Disease control OngoingWithin this exploratory multicohort phase II trial, SAKK aims to evaluate a PET/CT and ctDNA oriented therapy in DLBCL in order to test the following working hypothesis. * acalabrutinib-R-CHOP may improve the progression free survival in genetically defined DLBCL harboring the M…
Phase 2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Promising drug cocktail may stall aggressive prostate cancer
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety (including evaluating side effects) of combination of olaparib and abiraterone versus placebo and abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) who have received no prior cytot…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug inclisiran aims to slash cholesterol after heart attacks
Disease control CompletedThe purpose of this study is to study the effectiveness of implementation of a systematic LDL-C management pathway including treatment with inclisiran in participants who have experienced a recent acute coronary syndrome (ACS) and have an increased LDL-cholesterol (≥70 mg/dL) des…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Timing of chemo may boost rectal cancer remission
Disease control OngoingThe purpose of this study is to identify the most promising treatment sequence in total neoadjuvant therapy for locally advanced rectal cancer with a high risk of recurrence.
Phase 2 • Sponsor: Institute of Oncology Ljubljana • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Could a sleep apnea implant sharpen minds in down syndrome?
Disease control OngoingThis study is a prospective, single-arm study conducted under a common implant and follow-up protocol. The objective will be to follow fifty-seven (57) adolescents and young adults (10-21 years of age), with Down syndrome, moderate to severe sleep apnea, and post-adenotonsillecto…
Sponsor: Inspire Medical Systems, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Blood-Filtering therapy may tame rare brain inflammation in children
Disease control CompletedThe purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for kids with liver cancer: tailored chemotherapy trial launches
Disease control Recruiting nowHepatoblastoma is the most common malignant liver tumor in infants and preschool children, comprising 65% of pediatric liver malignancies in those under 15, with its incidence on the rise in recent years \[1\]. Standard therapy combines surgical resection and chemotherapy: early-…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Speeding stroke care: direct to angio suite could save brain tissue
Disease control Recruiting nowThe WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.
Sponsor: Philips Clinical & Medical Affairs Global • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Precision radiation may tame rising PSA after prostate surgery
Disease control OngoingThis phase II trial investigates the effect of extremely hypofractionated intensity modulated stereotactic body radiotherapy in treating patients with prostate cancer that has rising prostate specific antigen (PSA) after radical prostatectomy. Stereotactic body radiation therapy …
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Green light during surgery may spare patients from lifetime of pills
Prevention Recruiting now* Hypoparathyroidism is the most common complication after a total thyroidectomy surgery. It becomes permanent after 6 months. * Untreated permanent hypoparathyroidism is a source of numerous complications in general and therefore requires lifelong replacement therapy resulting i…
Phase 3 • Sponsor: University Hospital, Brest • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
Can a shorter chemo combo tame High-Risk neuroblastoma?
Disease control OngoingThe purpose of the study is to find out whether N9 is a safe and effective treatment for children with neuroblastoma. N9 includes 3 different combinations of chemotherapy drugs that are given at different times - Cyclophosphamide, topotecan, and vincristine (CTV), Ifosfamide, car…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New technique may spare tiniest babies from breathing tubes
Disease control CompletedThe purpose of this study is to evaluate the effect of LISA used in the delivery room (DR) in decreasing the intubation rates in preterm infants at 22-25 weeks gestational age (GA), during first 72 hours compared to the standard approach of stabilization on nasal CPAP in the DR a…
Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for advanced breast cancer: umbrella trial tests multiple drug cocktails
Disease control Recruiting nowThis is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with breast cancer. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical …
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New DNA vaccine shows promise against deadly MERS virus
Vaccine CompletedThe purpose of this Phase 2a, randomized, blinded, placebo-controlled, multi-center study is to evaluate the safety, tolerability and immunogenicity of INO-4700 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA™ 2000 device in healthy…
Phase 2 • Sponsor: Inovio Pharmaceuticals • Aim: Vaccine
Last updated Jun 27, 2026 08:12 UTC
-
New hope for kids with brain tumors: targeted drug mirdametinib enters trial
Disease control Recruiting nowThis is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Phase 1/2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immunotherapy combo shows promise in slowing advanced breast cancer
Disease control OngoingThe safety and efficacy of pembrolizumab plus the investigator's choice of chemotherapy will be assessed compared to placebo plus the investigator's choice of chemotherapy in the treatment of chemotherapy-candidate hormone receptor-positive, human epidermal growth factor receptor…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a second antibiotic powder slash infection risk in severe fractures?
Disease control CompletedThe overall objective is to compare the effect of Vancomycin and Tobramycin powder combined (treatment) to Vancomycin powder (control) in the reduction of post-fixation infections of tibial plateau and tibial pilon fractures at high risk of infection (collectively considered the …
Phase 3 • Sponsor: Major Extremity Trauma Research Consortium • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Digital tools may help osteoarthritis patients avoid surgery
Disease control CompletedMany individuals with osteoarthritis (OA) (up to 45%) are referred to an orthopaedic surgeon for a joint replacement prematurely or will not be candidates for surgery. These individuals need appropriate (non-operative) care to help reduce their pain and enhance their mobility. We…
Sponsor: Western University, Canada • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC